At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 90 enrolled
Drug / intervention
Indacaterol 300 μg +1 moredrug
Likely dose
Indacaterol 300 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 3 clinical trial evaluating Indacaterol 300 μg and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 90 participants across 20 sites in 6 countries.
Detailed Summary
This study compared the effect of indacaterol (300 μg once daily \[od\]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesBelgium, Canada, Denmark, Italy, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartApr 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedFeb 21, 2008
Enrollment StartApr 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.4 years ago
Interventions
Indacaterol 300 μgdrug
Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Placebodrug
Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.